Replies to post #6183 on Halozyme Therapeutics Inc (HALO)

[maumar]

It's possible a large company may be a little less eager to sign new deals but I'm not sure that affects Halo's current value.

I think this was another piece of good news for Halo today since I'm assuming the PR is referring to the Enhanze formulation of efgartigimod.

"argenx expects to redeem the PRV for a future marketing application for its FcRn antagonist efgartigimod. It will not be used for the BLA filing of intravenous efgartigimod in generalized myasthenia gravis, which is on track to be submitted in 2020."

https://finance.yahoo.com/news/argenx-enters-agreement-acquire-priority-060000295.html